Senior Bioinformatics Analyst

Institution/Company:
Princess Margaret Cancer Centre - UHN
Location:
Toronto, ON, Canada
Job Type:
  • Staff
Degree Level Required:
Masters
Apply Now

Senior Bioinformatics Analyst

We are seeking a highly motivated individual to maintain large-scale bioinformatics projects, analyze high-throughput data and oversee computational activities in the lab. This individual will work closely with computational biology trainees, research technicians and our clinical research coordinator. Within our academic environment, this position allows to make a significant contribution to cancer research and directly impact on our patients’ lives, by nature of our strong ties to the clinic.

Responsibilities:

The individual will be responsible for maintaining large omics datasets, deploying state-of-the-art computational tools and developing methods, if needed. The individual will also be responsible for ensuring reproducibility of findings, presenting results to internal and external stakeholders and supervising more junior colleagues.

Qualifications:

  • At minimum, a Bachelor’s degree in bioinformatics, computer science, statistics, and or Master’s degree preferred
  • At minimum, six (6) years of related experience
  • Strong background with Unix/Linux, Perl and/or Python.
  • Expertise with R and Bioconductor.
  • Advanced knowledge of NGS platforms and datatypes (FASTQ, BAM, VCF, etc).
  • Experience with analysis of targeted, exome or genome sequencing data.
  • Prior experience with cancer genomics is required.
  • Solid skills in statistical analysis (ANOVA, regression, clustering, phylogenetics, survival).
  • Experience with machine learning and data modelling is an asset.
  • Excellent communication skills.
  • Willingness to work in a team environment.

Additional Information

Our research group at Princess Margaret focuses on lymphoid malignancies and, in particular, on scenarios that are associated with poor outcome such as early progression after treatment, transformation to aggressive lymphoma and relapse in the central nervous system. We are applying cutting-edge tools to primary patient samples to unravel tumour heterogeneity and to develop novel, innovative biomarkers to predict outcome in lymphoma. Our ultimate goal is to improve patient outcomes through a better understanding of the diversity of responses to treatment and by tailoring therapy to each individual patient. See our lab website for further information: www.kridel-lab.ca.

Keywords: